Jump Financial’s Cymabay Therapeutics CBAY Stock Holding History

Jump Financial’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-63,684	Closed	-$950K	–	2376
2023 Q3	$950K	Buy	+63,684	New	+$844K	0.04%	694
2023 Q1	–	Sell	-70,801	Closed	-$444K	–	2154
2022 Q4	$444K	Buy	+70,801	New	+$269K	0.02%	834
2021 Q2	–	Sell	-40,700	Closed	-$185K	–	1461
2021 Q1	$185K	Sell	40,700 -19,990	-33%	-$108K	0.02%	771
2020 Q4	$348K	Buy	+60,690	New	+$459K	0.06%	537

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jump Financial's CBAY Position: Q4 2023 in Review

Jump Financial sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 63,684 shares — an estimated $950K sold.

Jump Financial first reported a position in CBAY in Q4 2020 and held it in 4 quarters. The position peaked at $950K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Jump Financial reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Jump Financial sold 63,684 Cymabay Therapeutics shares in Q4 2023, an estimated $950K.
Jump Financial first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 4 quarters.
Jump Financial's Cymabay Therapeutics position peaked at $950K in Q3 2023.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Jump Financial's 13F filing for Q4 2023, filed 7 Feb 2024.